TFRC and myelodysplastic syndrome: Consistent with a previous report, (41) MDS-RS cells treated with erythropoietin were blocked in differentiation after 14 days and amassed in CD71-CD235a- and CD71+CD235a- fractions, and only a few cells matured into CD71-CD235a+ cells (Fig 6B).